Caveolin-1 is an essential structural constituent of caveolae implicated in mitogenic signalling, oncogenesis, angiogenesis, neurodegenerative diseases and senescence. It is highly expressed in some tumours in vivo and this is associated with increased tumour aggressiveness, metastatic potential and suppression of apoptosis. In prostate, pancreas, thyroid, aggressive breast and bladder carcinomas the increase in caveolin-1 expression is frequently associated with acquisition of multidrug resistance to chemotherapy. In this study we show for the first time a therapeutic activity by Fenretinide, a synthetic derivative of retinoic acid, in osteosarcoma and glioblastoma cells. Results show also for the first time that Caveolin-1 is a molecular target of Fenretinide in these tumours, where its expression is down-regulated by the drug. The mechanism is p53-independent. As the downstream target of caveolin-1 downregulation, first results seem to exclude the ERK/pERK MAP kinases pathway. In each cell line the caveolin-1 expression did correlate with a negative estrogen receptor phenotype, as evaluated in the cytosol: this is in the line with recent results by others, indicating a cause-effect relationship between a high Caveolin-1 expression and the loss of ER in the cytosol. The capability of fenretinide to target and down-regulate caveolin-1 may have a key role to decrease tumour aggressiveness and to re-establish chemosensitivity in these tumours.

Caveolin-1 as a novel target of therapeutic activity of fenretinide in osteosarcoma and glioblastoma in vitro

GASPERI CAMPANI, ANNA;BAIOCCHI, DANIELA;ROSSI, ALESSANDRA;RONCUZZI, LAURA
2005

Abstract

Caveolin-1 is an essential structural constituent of caveolae implicated in mitogenic signalling, oncogenesis, angiogenesis, neurodegenerative diseases and senescence. It is highly expressed in some tumours in vivo and this is associated with increased tumour aggressiveness, metastatic potential and suppression of apoptosis. In prostate, pancreas, thyroid, aggressive breast and bladder carcinomas the increase in caveolin-1 expression is frequently associated with acquisition of multidrug resistance to chemotherapy. In this study we show for the first time a therapeutic activity by Fenretinide, a synthetic derivative of retinoic acid, in osteosarcoma and glioblastoma cells. Results show also for the first time that Caveolin-1 is a molecular target of Fenretinide in these tumours, where its expression is down-regulated by the drug. The mechanism is p53-independent. As the downstream target of caveolin-1 downregulation, first results seem to exclude the ERK/pERK MAP kinases pathway. In each cell line the caveolin-1 expression did correlate with a negative estrogen receptor phenotype, as evaluated in the cytosol: this is in the line with recent results by others, indicating a cause-effect relationship between a high Caveolin-1 expression and the loss of ER in the cytosol. The capability of fenretinide to target and down-regulate caveolin-1 may have a key role to decrease tumour aggressiveness and to re-establish chemosensitivity in these tumours.
25
25
GASPERI CAMPANI A.; BAIOCCHI D; MARTI G; ROSSI AL; RONCUZZI L
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11585/3494
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact